Burning Rock Biotech Limited
BNRHealthcareNASDAQDiagnostics & Research · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Burning Rock Biotech Limited focuses on Diagnostics & Research services and products. Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. Valued at $124.7M, BNR is a micro-cap name in its sector. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services.
Market Cap
$124.7M
Beta
1.29
P/E (TTM)
—
P/E (Fwd)
-20.38
EPS (TTM)
$-0.80
EPS (Fwd)
$-0.58
ROE
-12.8%
ROA
-5.2%
Cash
$416.8M
Total Debt
$45.1M
Free CF
$13.0M
52W Change
1.0%
Annual Financials
Cash vs Debt
Where BNR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, BNR finished 6.82% below its 150-day moving average ($13.19) and 27.19% below its 200-day moving average ($16.88). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BNR overbought or oversold?
At the October 20, 2026 close, BNR's RSI(14) was 17.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Burning Rock Biotech Limited holds $416.8M in cash against $45.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $13.0M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -12.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $563.2M (2022) to $539.6M (2025).
With cash comfortably exceeding debt, BNR has financial flexibility that may help navigate uncertain periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Burning Rock Biotech Limited and its sector.